Susquehanna Advisors Group Inc. acquired a new stake in shares of The Chemours Company (NYSE:CC - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 74,219 shares of the specialty chemicals company's stock, valued at approximately $1,254,000.
A number of other large investors have also bought and sold shares of CC. GAMMA Investing LLC increased its stake in Chemours by 99.7% in the 4th quarter. GAMMA Investing LLC now owns 1,532 shares of the specialty chemicals company's stock worth $26,000 after purchasing an additional 765 shares during the period. Quadrant Capital Group LLC increased its stake in Chemours by 100.4% in the 4th quarter. Quadrant Capital Group LLC now owns 2,234 shares of the specialty chemicals company's stock worth $38,000 after purchasing an additional 1,119 shares during the period. Aster Capital Management DIFC Ltd bought a new stake in shares of Chemours in the 4th quarter worth approximately $48,000. KBC Group NV grew its position in shares of Chemours by 38.2% in the 4th quarter. KBC Group NV now owns 6,176 shares of the specialty chemicals company's stock worth $104,000 after buying an additional 1,708 shares during the last quarter. Finally, Sterling Capital Management LLC grew its position in shares of Chemours by 54.8% in the 4th quarter. Sterling Capital Management LLC now owns 8,453 shares of the specialty chemicals company's stock worth $143,000 after buying an additional 2,991 shares during the last quarter. 76.26% of the stock is owned by hedge funds and other institutional investors.
Chemours Stock Performance
NYSE CC traded down $0.08 during trading hours on Friday, hitting $12.36. The company's stock had a trading volume of 1,658,033 shares, compared to its average volume of 1,868,506. The Chemours Company has a 12 month low of $9.33 and a 12 month high of $29.21. The company's 50 day simple moving average is $13.30 and its two-hundred day simple moving average is $17.03. The company has a debt-to-equity ratio of 6.70, a current ratio of 1.68 and a quick ratio of 0.92. The company has a market cap of $1.85 billion, a P/E ratio of 21.68 and a beta of 1.84.
Chemours (NYSE:CC - Get Free Report) last announced its quarterly earnings results on Tuesday, February 18th. The specialty chemicals company reported $0.11 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.10 by $0.01. The firm had revenue of $1.36 billion for the quarter, compared to the consensus estimate of $1.37 billion. Chemours had a net margin of 1.51% and a return on equity of 26.54%. As a group, sell-side analysts expect that The Chemours Company will post 2.03 EPS for the current fiscal year.
Chemours Dividend Announcement
The business also recently declared a quarterly dividend, which was paid on Friday, March 14th. Stockholders of record on Friday, February 28th were issued a dividend of $0.25 per share. This represents a $1.00 dividend on an annualized basis and a dividend yield of 8.09%. The ex-dividend date was Friday, February 28th. Chemours's payout ratio is presently 175.44%.
Wall Street Analyst Weigh In
A number of equities research analysts have recently weighed in on the company. Barclays cut their price objective on Chemours from $19.00 to $16.00 and set an "equal weight" rating on the stock in a research report on Tuesday, April 1st. Truist Financial cut their price objective on Chemours from $27.00 to $22.00 and set a "buy" rating on the stock in a research report on Monday, April 14th. The Goldman Sachs Group cut their price objective on Chemours from $24.00 to $21.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 7th. BMO Capital Markets dropped their price target on Chemours from $34.00 to $27.00 and set an "outperform" rating on the stock in a research report on Wednesday, February 19th. Finally, Mizuho set a $15.00 price target on Chemours in a research report on Tuesday, April 15th. Four analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $21.56.
View Our Latest Analysis on Chemours
About Chemours
(
Free Report)
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.
Featured Articles
Before you consider Chemours, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemours wasn't on the list.
While Chemours currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
